Interest in nanotechnology, including both polymeric and lipidic nanoparticles, has grown significantly in the last decade. The tremendous success of mRNA-lipid nanoparticle (LNP)-based vaccines during the COVID-19 pandemic has led to further explosive growth in development and created new opportunities in this area. The unprecedented speed of development of the COVID-19 LNP-based vaccines was, to a large extent, built upon foundational work performed over the last 10–15 years in LNP platform development.
This is why Dolomite and Phosphorex partnered to bridge their complementary areas of expertise:
Dolomite Microfluidics leverages 20 years of industry-leading Microfluidics technology, product engineering and applications knowledge to design and manufacture cutting-edge particle generation platforms, such as the Automated Nanoparticle (ANP) System enabling customers to fast-track their own product development processes.
Phosphorex brings extensive expertise and capabilities in nanoparticle-based formulations, analytical characterization, process development, scale-up, and manufacturing. Phosphorex has developed a comprehensive approach to optimize the LNP development process and streamline transition into clinical manufacturing.
Webinar details: |
|
Date: Tuesday, 8th March 2022 Time: 09:00 PST | 12:00 EST | 17:00 GMT Event type: Webinar – Live |
Read our new Application Note on the controlled synthesis of lipid nanoparticles using the ANP System and learn about the research done by our Experts on the key parameters involved in tuning LNPs’ size, and a comparison between the protocol and continuous mode to demonstrate the transferability of the process parameters for bulk production of LNPs.